We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Astex Pharmaceuticals, Inc. (MM) | NASDAQ:ASTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.495 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
| SGI-110 | Abstract # A256 | |
| Poster Presentation | Sunday, Oct. 20 | 12:30 - 7:30 p.m. EDT |
| Improved Antitumor Activity by Sequencing SGI-110 with CTLA-4 Blockade in a Syngenic Mouse Model | ||
| XIAP | Abstract #A55 | |
| Poster Presentation | Sunday, Oct. 20 | 12:30 - 7:30 p.m. EDT |
| Potent, dual cIAP1/XIAP antagonists induce apoptosis in a melanoma stem cell population | ||
| LEE011 | Abstract #PR02 | |
| Proffered Paper Session | Sunday, Oct. 20 | 5:45 – 6 p.m. EDT |
| Abstract #B264 | ||
| Novartis Poster Presentation | Monday, Oct. 21 | 12:30 – 3 p.m. & 6:30 – 7:30 p.m. EDT |
| LEE011- An orally bioavailable, selective small molecule inhibitor of CDK4/6: Reactivating Rb in cancer | ||
| LEE011 | Abstract #A276 | |
| Novartis Poster Presentation | Sunday, Oct. 20 | 12:30 - 3 p.m. & 6:30 – 7:30 p.m. EDT |
| Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas | ||
Select posters will be made available for viewing on the Astex website http://astx.com/pipeline/publications/.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. Astex is developing a proprietary pipeline of novel therapies and is creating de-risked products for collaborations with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
Hot Features
Premium
CONTACT: Timothy L. Enns
Astex Pharmaceuticals, Inc.
Senior Vice President
Corporate Communications & Marketing
Tel: +1 (925) 560-2810
E-mail: tim.enns@astx.com
Susanna Chau
Astex Pharmaceuticals, Inc.
Manager
Tel: +1 (925) 560-2845
E-mail: susanna.chau@astx.com
1 Year Astex Pharmaceuticals, Inc. (MM) Chart |
1 Month Astex Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
